# HPLC/UPLC instruments for biopharma Bench-top liquid chromatography systems — HPLC and ultra-high-performance UPLC platforms — that separate and quantify proteins, peptides, small molecules and impurities ahead of UV, fluorescence or mass-spectrometry detection, the workhorse instrument for biopharma purity testing, release assays and formulation characterization. Source: https://en.bioecon.ru/technology/hplc-uplc-instruments/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: US FDA 21 CFR Part 11 + USP <621>/<1058> for chromatographic system validation | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] HPLC and UPLC instruments separate the components of a liquid sample by pumping it under high pressure through a column packed with a stationary phase, resolving proteins, peptides, small molecules and impurities into discrete, individually detectable peaks before UV, fluorescence, or mass-spectrometry detection. Ultra-high-performance liquid chromatography (UPLC/UHPLC) pushes the same separation principle to sub-2-micron particle columns and pressures above 15,000 psi, delivering sharper peaks, faster run times and higher resolution than conventional HPLC's 3-5-micron media. The instrument is the single most common analytical workhorse in a biopharma QC lab: a purity assay, a charge-variant analysis, a host-cell-protein clearance check and a formulation stability study all run on the same basic pump-column-detector architecture, differing mainly in column chemistry and detection mode. Speed has become a competitive axis in the current generation — vendors report run-time reductions of 2-3x for specific bioseparation applications such as GLP-1 peptide characterization and LNP component analysis, driven by new reversed-phase column chemistries paired with faster-scanning detectors. The key directions of HPLC/UPLC instrumentation are: 1. **Ultra-high-performance liquid chromatography (UPLC/UHPLC):** sub-2-micron column particles and pressures above 15,000 psi deliver sharper resolution and faster run times than conventional HPLC, now the default for high-throughput biopharma QC. 2. **Reversed-phase bioseparation chromatography (RP Bioseparation):** column chemistries purpose-built for peptide, protein and LNP-component separation, delivering faster run times for applications such as GLP-1 characterization and mRNA-LNP QC. 3. **Size-exclusion and ion-exchange chromatography (SEC/IEX):** separation by molecular size or charge rather than hydrophobicity, used for aggregate quantitation and charge-variant analysis of therapeutic proteins. 4. **LC-MS hyphenation (LC-MS Coupling):** liquid chromatography feeding directly into a mass spectrometer, turning a chromatographic separation into a combined identity and purity measurement. ### Sectoral value chain ``` [Liquid sample] ──> [High-pressure pump] ──> [Column separation] ──> [Detection: UV/fluorescence/MS] │ (peak identification) │ ▼ [Purity/identity/quantitation report] <─── [Software: peak integration, chromatogram comparison] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Sample preparation** | The sample is filtered, diluted or derivatized to a form compatible with the column and detector. | **In:** raw protein/peptide/small-molecule sample. **Out:** injection-ready sample. | | **High-pressure pumping** | A binary or quaternary pump delivers a precise solvent gradient at pressures up to and beyond 15,000 psi for UPLC. | **In:** mobile-phase solvents. **Out:** pressurized, gradient-controlled solvent flow. | | **Column separation** | The sample partitions between mobile and stationary phases as it traverses the column, eluting components at different retention times. | **In:** injected sample, solvent flow. **Out:** time-resolved eluent stream. | | **Detection** | UV/Vis, fluorescence or mass-spectrometry detectors measure each eluting component as it exits the column. | **In:** eluent stream. **Out:** raw chromatogram signal. | | **Software: peak integration** | Chromatography data software integrates peak areas, assigns retention-time identities and flags new or shifted peaks. | **In:** raw chromatogram. **Out:** integrated peak table, identified/quantified species. | | **Purity/release reporting** | Results are compared against a validated method specification for a purity, identity or release determination. | **In:** peak table. **Out:** purity/identity report, GxP release record. | Cross-cutting technologies of the sector: - **Sub-2-micron core-shell particles:** superficially porous column media approach UPLC resolution at conventional HPLC pressures, extending high-resolution separation to instruments without full UHPLC pump capability. - **Multi-detector hyphenation:** photodiode-array UV, fluorescence and mass-spectrometry detectors are increasingly run in parallel off a single chromatographic separation. - **Automated method-transfer software:** vendor tools now translate a validated method between HPLC and UPLC platforms, adjusting flow rate and gradient to preserve selectivity across instrument generations. --- ## US The US hosts the category's largest instrument makers and the deepest biopharma purity-testing and release-assay demand, spanning discovery characterization through GxP QC. ### bioseparation column chemistry, UHPLC speed leadership, mass-spec-coupled release testing - **Waters Corporation:** the ACQUITY Premier UPLC platform and new reversed-phase bioseparation columns deliver up to 3x faster GLP-1 peptide characterization and 2x faster LNP-component analysis, alongside LC-MS platform methodologies supporting upstream bioprocess optimization. - **Agilent Technologies:** the 1290 Infinity II binary UHPLC system extends the established 1290 Infinity line with higher throughput and resolution for biopharma and small-molecule analysis. - **Thermo Fisher Scientific:** the Vanquish Horizon UHPLC system is positioned for high-throughput liquid chromatography, emphasizing maximized data output and minimized downtime for productivity-focused QC labs. --- ## CN No China-headquartered HPLC/UPLC instrument maker cleared this screening round with confirmed, on-domain evidence; demand is driven by China's expanding biopharma purity-testing and QC-release base, currently served largely through the same global vendors' regional distribution and applications-support networks. ### import-dependent instrumentation, domestic biopharma QC demand, distributor-served market - **Global vendor distribution:** Waters, Agilent, Thermo Fisher and Shimadzu each maintain China sales and applications-support organizations serving domestic biopharma and QC laboratories. - **Domestic biopharma QC build-out:** China's growing biologics manufacturing and purity-testing base is the main demand driver for HPLC/UPLC instrumentation, without a confirmed domestic instrument originator identified in this screen. - **Screening note:** two candidate China-headquartered instrument makers were probed and neither returned confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed. --- ## EU Germany contributes both a global instrument giant's manufacturing base and an independent owner-managed specialist, giving Europe a distinct competitive shape from the US's vendor concentration. ### owner-managed instrument engineering, FPLC/UHPLC bio-application focus, independent European specialist - **Knauer (Germany):** based in Berlin and family-owned since 1962, Knauer's AZURA Bio Lab FPLC and AZURA HTQC UHPLC systems are positioned specifically for biopharma and life-science separation applications, an independent alternative to the US instrument majors. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Waters Corporation** | 🇺🇸 USA | *ACQUITY Premier UPLC* | Reversed-phase bioseparation columns; 2-3x faster GLP-1/LNP analysis | Commercial, public (NYSE: WAT) | | **Agilent Technologies** | 🇺🇸 USA | *1290 Infinity II* | Binary UHPLC; high-throughput biopharma and small-molecule analysis | Commercial, public (NYSE: A) | | **Thermo Fisher Scientific** | 🇺🇸 USA | *Vanquish Horizon UHPLC* | High-throughput liquid chromatography for productivity-focused QC | Commercial, public (NYSE:TMO) | | **Shimadzu** | 🇯🇵 Japan | *Nexera X4 UHPLC* | Low-dispersion fluidics; high-speed, high-sensitivity separation | Commercial, public (TYO:7701) | | **Knauer** | 🇩🇪 Germany | *AZURA Bio Lab FPLC, AZURA HTQC UHPLC* | Owner-managed since 1962; biopharma/life-science-focused platforms | Commercial | --- ## Tech stack and innovations The stack layers high-pressure fluidics, column chemistry and detection on a common chromatography-data-software backbone, with the UPLC/HPLC choice driven by the resolution and throughput the application requires. 1. **Sub-2-micron UPLC column technology:** - Smaller stationary-phase particles increase the theoretical plate count per unit column length, sharpening peaks and improving resolution at the cost of higher backpressure. - Pumps rated above 15,000 psi and low-dispersion flow paths are required to run these columns without band-broadening that would erase the resolution gain. 2. **Reversed-phase bioseparation column chemistry:** - Column surface chemistries engineered specifically for peptide and protein hydrophobicity profiles improve peak shape and resolution for biotherapeutic molecules versus general-purpose reversed-phase media. - Purpose-built chemistries for GLP-1 peptides and LNP lipid components deliver measured 2-3x run-time reductions over prior-generation columns. 3. **LC-MS hyphenation:** - The chromatography outlet feeds directly into a mass spectrometer's ionization source, so each separated peak carries both a retention time and a mass spectrum. - Turns a purity separation into a combined identity-and-purity measurement in one run, supporting upstream bioprocess optimization and impurity characterization. --- ## Value chains and production pipelines ### Industrial pipeline of a biopharma purity/release chromatography run (USP <621>/<1058> / 21 CFR Part 11) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Sample preparation │ ───> │ 2. Injection & pumping │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Detection │ <─── │ 3. Column separation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Peak integration │ ───> │ 6. Purity/release report │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Sample preparation The sample is filtered to remove particulates and diluted or derivatized as needed to match the column's loading capacity and the detector's linear response range. #### Stage 2: Injection and pumping An autosampler injects a precise volume onto the column while a binary or quaternary pump delivers a controlled solvent gradient at pressures appropriate to the column's particle size. #### Stage 3: Column separation The sample partitions between the mobile phase and the column's stationary phase, separating into discrete components that elute at characteristic retention times. #### Stage 4: Detection UV/Vis, fluorescence or mass-spectrometry detectors measure each eluting peak, generating the raw chromatographic signal. #### Stage 5: Peak integration Chromatography data software integrates peak areas, assigns identities by retention time or mass, and flags any new, missing or shifted peaks relative to a reference method. #### Stage 6: Purity or release report The integrated results are compared against a validated method specification under USP <621>/<1058>, with a 21 CFR Part 11-compliant audit trail generating the purity, identity or batch-release determination. ---